Rachael Ahern

Rachael Ahern has a wealth of experience in the biotechnology and pharmaceutical industries. Rachael is currently working as the Associate Director of Quality at Tessera Therapeutics, a position they have held since April 2022. Prior to this role, they served as the Associate Director of Analytical Development at Tessera Therapeutics from June 2021 to May 2022.

Before joining Tessera Therapeutics, Rachael worked at Vedere Bio as a Senior Manager of Analytical Development from January 2020 to April 2021. Rachael also worked at Homology Medicines, Inc. as a Scientist I from June 2019 to December 2019 and at Voyager Therapeutics, Inc. in various roles including Scientist I, Senior Associate Scientist I, and Associate Scientist II from November 2015 to June 2019.

Rachael started their career at Cyprotex as an Associate Scientist in in vitro toxicity and ADME/DMPK from October 2013 to April 2015. Rachael also gained experience as a Biology Department tutor at Northeastern University and as a Medical Assistant at Mystick Women's Health, Biogen, and OB/GYN Associates.

Overall, Rachael Ahern has a diverse background in the biotechnology and pharmaceutical fields, with experience in quality, analytical development, process analytics, and in vitro toxicity.

Rachael Ahern attended Northeastern University from 2008 to 2013, where they obtained a Bachelor of Science (BS) degree in biology with a minor in psychology. Rachael also holds additional certifications in JMP Software from SAS, which were obtained in 2019.